{"id":"W2621656000","doi":"10.1016/s1470-2045(17)30404-7","title":"Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":74,"is_retracted":false,"has_abstract":true,"ca_institutions":"Ontario Institute for Cancer Research","funders":"Eisai; National Institute for Health and Care Research; Cancer Research UK; University College London; Les Laboratories Pierre Fabre; AstraZeneca; Celgene; Genomic Health; Research England; Pfizer; Amgen","keywords":"Epirubicin; Medicine; Capecitabine; Cyclophosphamide; Breast cancer; Internal medicine; Fluorouracil; Gastroenterology; Chemotherapy; Cancer; Surgery; Colorectal cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002662627,0.000535012,0.002095292,0.00003901142,0.0008342415,0.0002349195,0.001214407,0.0002931716,0.0001566493],"category_scores_gemma":[0.001755906,0.0002737628,0.0002053221,0.0001011568,0.0003970827,0.00002976712,0.0002548296,0.0002581112,0.000002032246],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001862813,"about_ca_system_score_gemma":0.0007360952,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001202052,"about_ca_topic_score_gemma":0.003300133,"domain_scores_codex":[0.996186,0.001347622,0.0007546495,0.0007249715,0.0002490882,0.0007376834],"domain_scores_gemma":[0.9957924,0.002083959,0.0008458201,0.0009262161,0.0002227178,0.0001288947],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9426078,0.001171328,0.00003798711,0.00001050004,0.001554471,0.00003498931,0.0004227812,0.000006032955,0.00920506,0.00001405914,0.01575367,0.02918131],"study_design_scores_gemma":[0.9614261,0.008458877,0.0001388696,0.00002108364,0.000554692,0.00002371246,0.0002871706,0.000053893,0.002721688,0.00004956694,0.0259217,0.0003426207],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9494686,0.006183103,0.0000551084,0.01554399,0.00189758,0.02423112,0.001585006,0.0000234897,0.001012055],"genre_scores_gemma":[0.9661761,0.01412382,0.0002835027,0.002129403,0.001616141,0.01485771,0.0001809829,0.00006278354,0.0005695607],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02883869,"threshold_uncertainty_score":0.9999714,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08496628285504446,"score_gpt":0.4261559906783022,"score_spread":0.3411897078232577,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}